Active Biotech AB Invites to

LUND, SWEDEN--(Marketwire - May 29, 2012) - Active Biotech invites analysts, investors and media to Capital Markets Day on June 14, 2012.

When:    Thursday, June 14, 2012 at 2-4 p.m. CET.

Where:   Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm, Sweden.

To attend:

Please send name & contact details to or call +46 (0)46 19 20 00, no later than June 10, 2012.

Active Biotech participants:
Tomas Leanderson, President & CEO
Göran Forsberg, Chief Business Officer

Overview of Active Biotech's project portfolio

The Capital Markets Day will also be available to follow via Active Biotech's website

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for Systemic Sclerosis and RhuDex® for RA. Please visit for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication 1:00 p.m. CET on May 29, 2012.

Active Biotech invites to Capital Markets Day:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE [HUG#1615546]

For further information, please contact:
Hans Kolam
Phone: +46 (0)46 19 20 44
E-mail: Email Contact

Back to news